Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
Virios Therapeutics, Inc. (VIRI) is a development-stage biotechnology company dedicated to advancing novel antiviral therapies aimed at treating diseases associated with viral-triggered abnormal immune responses, such as fibromyalgia (FM) and Long-COVID (LC). With a focus on innovation and patient care, Virios Therapeutics is working on two main product candidates, IMC-1 and IMC-2.
IMC-1 is designed to synergistically suppress the activation and replication of herpesvirus, specifically targeting the Epstein-Barr virus (herpesvirus HHV-4). This approach aims to alleviate symptoms by addressing the underlying viral triggers of immune response abnormalities. IMC-2, a combination of valacyclovir and celecoxib, is another promising candidate in their pipeline.
Virios Therapeutics is committed to advancing their research and development efforts to bring these groundbreaking therapies to market. The company's headquarters is located at 1837 Commons North Drive, Tuscaloosa, Alabama, United States. Their team, led by Chairman and CEO Greg Duncan, is dedicated to addressing unmet medical needs with innovative solutions.
The latest updates from Virios Therapeutics reflect their ongoing progress in clinical trials and strategic partnerships. For more information, investors and interested parties can contact their Investor Relations team at IR@Virios.com.
Virios Therapeutics (Nasdaq: VIRI) has received initial feedback from the FDA regarding its Phase 3 program proposal for IMC-1, a combination treatment targeting fibromyalgia. The FDA considers the proposal acceptable, pending review of final toxicology program results. The proposed Phase 3 program includes two controlled clinical studies and a long-term safety trial. Final toxicology results will be submitted in May 2023, with further updates expected as the FDA review progresses. This program aims to address the significant unmet medical need in the fibromyalgia community, as no new treatments have been FDA-approved for this condition in over a decade.
Virios Therapeutics (Nasdaq: VIRI) reported its financial results for Q4 and full-year 2022. The company experienced a significant reduction in R&D expenses, totaling $1.3 million in Q4 2022, down from $2.9 million in Q4 2021. General and administrative expenses also fell to $0.8 million in Q4 2022 from $1.3 million in Q4 2021. The net loss for Q4 2022 stood at $2.0 million, or $0.11 per share, compared to a loss of $4.5 million, or $0.54 per share, a year earlier. For the full year 2022, the net loss was $12.2 million, down from $16.0 million in 2021. As of year-end, the company held $7.0 million in cash, with funding anticipated through mid-2024 for ongoing programs.
FAQ
What is the current stock price of Virios Therapeutics (VIRI)?
What is the market cap of Virios Therapeutics (VIRI)?
What does Virios Therapeutics specialize in?
What are the main product candidates of Virios Therapeutics?
Where is Virios Therapeutics headquartered?
Who is the CEO of Virios Therapeutics?
How can I contact Virios Therapeutics for investor relations?
What is IMC-1 designed to target?
What diseases are Virios Therapeutics targeting with their therapies?
What does IMC-2 consist of?
Is Virios Therapeutics currently conducting clinical trials?
How does Virios Therapeutics approach the treatment of fibromyalgia and Long-COVID?
